BioNano Genomics, Inc. (NASDAQ: BNGO) reported Q2 revenue for the quarter came in at $1.18 million versus the consensus estimate of $860 thousand.

“We have made great strides towards validating the scientific credibility of our Saphyr System as we work to establish it as the new gold standard in cytogenetic methods. To that end, we saw leading researchers publish data showing 100% concordance with current cytogenetic methods,” said Erik Holmlin, Ph.D., CEO of Bionano. “Also, we are enabling researchers to develop an understanding of SARS-CoV-2, the virus that causes COVID-19, through our partnership with the structural variant consortium, formed by Dr. Ravindra Kolhe at Augusta University. The scope of work with the consortium was significantly expanded and now includes work analyzing samples from COVID-19 patients around the globe.”

For earnings history and earnings-related data on BioNano Genomics, Inc. (BNGO) click here.